Imaging response evaluation after neoadjuvant treatment in soft tissue sarcomas: Where do we stand?
CT, MRI, PET/CT
Imaging
Pathology
Sarcoma
Tumour response evaluation
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
12
08
2020
revised:
15
02
2021
accepted:
03
03
2021
pubmed:
25
3
2021
medline:
21
4
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
Soft tissue sarcomas (STS) represent a broad family of rare tumours for which surgery with radiotherapy represents first-line treatment. Recently, neoadjuvant chemo-radiotherapy has been increasingly used in high-risk patients in an effort to reduce surgical morbidity and improve clinical outcomes. An adequate understanding of the efficacy of neoadjuvant therapies would optimise patient care, allowing a tailored approach. Although response evaluation criteria in solid tumours (RECIST) is the most common imaging method to assess tumour response, Choi criteria and functional and molecular imaging (DWI, DCE-MRI and
Identifiants
pubmed: 33757836
pii: S1040-8428(21)00097-4
doi: 10.1016/j.critrevonc.2021.103309
pii:
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103309Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.